News

Alkermes Scheduled to Discuss Q1 Financial Performance Soon

Alkermes Scheduled to Discuss Q1 Financial Performance Soon

Alkermes to Present First Quarter Results on May 1

Alkermes plc (Nasdaq: ALKS) is set to hold a significant conference call on May 1, where they will discuss their financial results for the first quarter of the year. This event is anticipated to provide crucial insights into the company's performance and future strategies.

Conference Call and Webcast Details

The conference call will start at 8:00 a.m. ET, which corresponds to 1:00 p.m. BST. Interested parties can participate in the call by dialing the U.S. number +1 877 407 2988 or the international number +1 201 389 0923. The call will also be streamed live via a webcast, details of which can be found on the Investors section of Alkermes' corporate website.

Access to Webcast Replay

For those unable to join the live call, Alkermes will provide a replay of the webcast about two hours after the conclusion of the event. This replay will be accessible through Alkermes' website, ensuring that stakeholders can stay informed about the company's developments.

Understanding Alkermes plc

Alkermes plc is a renowned global biopharmaceutical company dedicated to advancing innovative medicines in the neuroscience sector. The company's offerings include proprietary products aimed at treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes is actively involved in the development of clinical and preclinical candidates aimed at neurological disorders like narcolepsy and idiopathic hypersomnia.

Headquarters and Operations

Headquartered in Ireland, Alkermes maintains a robust research and development presence with facilities located in Massachusetts and a manufacturing center in Ohio. This diverse operational footprint supports the company’s commitment to producing effective therapies while advancing groundbreaking research in its field.

Contact Information

For further inquiries, contact Jamie Constantine from Investor Relations at +1 781 873 2402. Alkermes remains committed to transparency and communication with its investors and stakeholders.

Frequently Asked Questions

When will Alkermes report its first quarter financial results?

Alkermes is scheduled to report its first quarter financial results on May 1.

How can I access the conference call?

You can access the conference call by dialing +1 877 407 2988 for U.S. callers or +1 201 389 0923 for international callers.

Is there a way to listen to the replay of the call?

Yes, a replay of the webcast will be available two hours after the event on Alkermes' website.

What therapeutic areas does Alkermes focus on?

Alkermes focuses on developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, among others.

Where is Alkermes headquartered?

Alkermes is headquartered in Ireland, with additional facilities in Massachusetts and Ohio.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing Insights: Man Group PLC's Position in Spectris plc

Updated Category News Views 315

Understanding Man Group PLC's Investment Position Man Group PLC, a primary player in investment management, recently announced its public interests regarding relevant securities in Spectris plc. This disclosure highlights its strategic investment and positions in the market. Key Information Disclosure As per regulatory requirements, Man Group PLC has provided essential...

Continue Reading
Coca Cola Surpasses Expectations Amidst Market Challenges

Updated Category News Views 357

Coca Cola Surpasses Expectations Amidst Market Challenges On a recent earnings announcement, The Coca Cola Company (NYSE: KO) exceeded Wall Street predictions, showcasing a resilient strategy to enhance revenue and earnings despite shifting consumer preferences. While demand for beverages has softened, Coca Cola's ability to raise prices proved beneficial, even as...

Continue Reading
Joget Enhances Application Development Using AI and Security

Updated Category News Views 86

Transforming Application Development with Joget AI The innovative Vibe Composition approach by Joget empowers enterprises to craft robust applications by utilizing trusted, composable components rather than traditional raw coding methods. This modern take on application development is encapsulated within the Joget AI Designer, making the process both efficient and secure....

Continue Reading
Gimme Credit Unveils Innovative Platform to Enhance Global Research

Updated Category News Views 215

Introducing Gimme Credit's New Client Platform Gimme Credit, a prominent independent provider of credit research and data, has recently launched a cutting-edge delivery platform. This initiative marks a significant step in the company's global expansion and innovation efforts. An Era of Growth and Technological Innovation The new platform utilizes a cloud-based...

Continue Reading
Comprehensive Overview of SCOR's Share and Voting Rights Data

Updated Category News Views 36

Understanding SCOR's Share Capital and Voting Rights In today's competitive landscape, it is crucial for companies to maintain transparency regarding their operations and shareholder information. SCOR, a notable player in the global reinsurance market, has recently provided an insightful declaration concerning its share capital and voting rights. This information...

Continue Reading